431 related articles for article (PubMed ID: 21112773)
1. Glypican-3: a new target for cancer immunotherapy.
Ho M; Kim H
Eur J Cancer; 2011 Feb; 47(3):333-8. PubMed ID: 21112773
[TBL] [Abstract][Full Text] [Related]
2. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
3. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.
Ho M
BioDrugs; 2011 Oct; 25(5):275-84. PubMed ID: 21942912
[TBL] [Abstract][Full Text] [Related]
4. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
Nishimura Y; Nakatsura T; Senju S
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma.
Allegretta M; Filmus J
Anticancer Agents Med Chem; 2011 Jul; 11(6):543-8. PubMed ID: 21554204
[TBL] [Abstract][Full Text] [Related]
7. [Cancer peptide vaccine targeted glypican-3 antigen].
Nakatsura T
Nihon Rinsho; 2017 Feb; 75(2):257-262. PubMed ID: 30562861
[TBL] [Abstract][Full Text] [Related]
8. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
[TBL] [Abstract][Full Text] [Related]
9. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
Sawada Y; Nakatsura T
Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
[TBL] [Abstract][Full Text] [Related]
10. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
11.
Chen K; Wu Z; Zhao H; Wang Y; Ge Y; Wang D; Li Z; An C; Liu Y; Wang F; Bi X; Wang H; Cai J; Ma C; Qu C
Cancer Immunol Res; 2020 Jan; 8(1):81-93. PubMed ID: 31666238
[TBL] [Abstract][Full Text] [Related]
12. Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3.
Chen JJ; Xie CM; Wang CR; Wan Y; Dong ZN; Li M; Xu WW
J Fluoresc; 2017 Jul; 27(4):1479-1485. PubMed ID: 28429175
[TBL] [Abstract][Full Text] [Related]
13. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
[TBL] [Abstract][Full Text] [Related]
14. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
[TBL] [Abstract][Full Text] [Related]
15. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
Gao W; Kim H; Ho M
PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
17. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z
Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy.
Hanaoka H; Nagaya T; Sato K; Nakamura Y; Watanabe R; Harada T; Gao W; Feng M; Phung Y; Kim I; Paik CH; Choyke PL; Ho M; Kobayashi H
Mol Pharm; 2015 Jun; 12(6):2151-7. PubMed ID: 25955255
[TBL] [Abstract][Full Text] [Related]
19. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
[TBL] [Abstract][Full Text] [Related]
20. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]